CPRX
Catalyst Pharmaceuticals Inc
NASDAQ: CPRX · HEALTHCARE · BIOTECHNOLOGY
$31.36
-0.03% today
Updated 2026-06-12
Market cap
$3.84B
P/E ratio
18.13
P/S ratio
6.43x
EPS (TTM)
$1.73
Dividend yield
—
52W range
$19 – $33
Volume
2.3M
Catalyst Pharmaceuticals Inc (CPRX) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed CPRX price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$31.36
Today
Analyst consensus
$32.17
+2.58% · 12M
2030 Base
$34.70
+10.65% future
NPV today
$23.92
@ 8% WACC
8 analysts:
3 Buy5 Hold0 Sell
Management guidance
Catalyst has NOT provided explicit 2026-2030 revenue guidance. Q1 2026 earnings call was cancelled due to pending Angelini Pharma acquisition announcement (May 7, 2026). Company guidance was last provided in Feb 2026 for full-year 2026 at $643.79M (+9.3% YoY), implying mid-single-digit growth trajectory post-acquisition close (Q3 2026). No long-term CAGR targets disclosed.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
CPRX · Catalyst Pharmaceuticals Inc · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$27.05
NPV today: $18.65
Base case (2030)
$34.70
NPV today: $23.92
Bull case (2030)
$65.28
NPV today: $45.01
WallStSmart.com
CPRX financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $0.6B | $0.6B | $0.7B | $0.8B | $0.9B | $1.0B |
| Revenue growth | 19.8% | 9.3% | 10.7% | 11.9% | 10.0% | 8.8% |
| Net margin | — | 39.4% | 40.5% | 41.8% | 42.8% | 43.5% |
| EPS | $1.96 | $2.06 | $2.34 | $2.69 | $3.02 | $3.33 |
| Diluted shares | — | 123M | 123M | 124M | 124M | 125M |
| Net debt | — | $-813.13M | $-952.78M | $-1.11B | $-1.28B | $-1.47B |
| P/S multiple | — | 3.0x | 3.0x | 3.0x | 3.0x | 3.0x |
| Implied price (base) | — | $22.32 | $25.03 | $28.25 | $31.44 | $34.70 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $1.0B | $1.0B | $1.0B |
| P/S multiple | 2.0x | 3.0x | 7.0x |
| Diluted shares | 125M | 125M | 125M |
| Net debt | $-1.47B | $-1.47B | $-1.47B |
| Implied P/E † | 8x | 10x | 20x |
| 2030 Price | $27.05 | $34.70 | $65.28 |
| NPV @ 8% | $18.65 | $23.92 | $45.01 |
† Implied P/E: Multiples remain elevated across all three scenarios because CPRX is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $34.70 base case
CPRX catalysts and risks
Growth catalysts
+ Angelini Pharma acquisition closing (Q3 2026, $31.50/share all-cash deal) — removes independent growth narrative but provides exit liquidity and access to Angelini's European/global distribution
+ FIRDAPSE generic entry delayed to January 2035 via Hetero Labs settlement — extends peak exclusivity window by ~9 years from original 2025-2026 generic threat
+ AGAMREE (vamorolone) ramp for Duchenne Muscular Dystrophy (DMD) — revenue grew 66.6% YoY in Q1 2026 ($11M+ quarterly run rate); Phase III data presented at 2026 MDA conference signals label expansion potential
+ FYCOMPA revenue stabilization in seizure disorder market — mature product but stable $40-50M annual revenue base
Key risks
- Acquisition integration risk under Angelini Pharma — deal subject to regulatory approval, financing certainty, and shareholder vote; potential for delayed close or failed transaction would reset valuation
- FIRDAPSE revenue sustainability post-generic entry (2035) — accounts for ~45-50% of current revenue; no approved successor therapy identified
- Rare disease market concentration — three drugs (FIRDAPSE, AGAMREE, FYCOMPA) comprise >95% of revenue; limited pipeline diversification increases dependency on label expansions and market share holds
- Slower organic growth post-acquisition — historical 19-85% YoY growth (2020-2023) unlikely to continue under larger parent; management guidance implies 9-10% 2026-2027 growth
Methodology · Catalyst Pharmaceuticals Inc 2030 stock forecast model
Catalyst Pharmaceuticals Inc 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 8 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (2% cumulative for CPRX by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($-1.47B by 2030) |
| 3. Time value | NPV calculated using 8% WACC (CAPM: beta 0.718) |
| 4. Multiple framework | P/S compresses with scale: bear 2.0x / base 3.0x / bull 7.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 20, 2026.
CPRX price target FAQ
What is the CPRX price target for 2030?
WallStSmart's Catalyst Pharmaceuticals Inc 2030 base case is $34.70 per share, with a bull case of $65.28 and bear case of $27.05. The NPV of the base case discounted to today at 8% WACC is $23.92.
How is the Catalyst Pharmaceuticals Inc 2030 stock forecast calculated?
The CPRX 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the CPRX price target account for dilution?
Catalyst Pharmaceuticals Inc is projected to grow diluted share count from 122M to 125M by 2030 (a 2% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 2%.
What is the analyst consensus on CPRX stock?
8 analysts cover CPRX with an average 12-month price target of $32.17. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.